Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schram

Showing results (81-90 of 186) with videos related to

Pageof 19
Sort By:
ESMO Open|August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsE Borazanci, A M Schram, E Garralda, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Future Oncology (London, England)|March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumorsAlison M Schram, John J Park, Antoine Italiano, et al.
British Journal of Cancer|September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David Hong, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic TrialAlison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular SubtypesJason C Chang, Michael Offin, Christina Falcon, et al.
Pageof 19

Showing results (81-90 of 186) with videos related to

Sort By:
Pageof 19
ESMO Open|August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsE Borazanci, A M Schram, E Garralda, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Future Oncology (London, England)|March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumorsAlison M Schram, John J Park, Antoine Italiano, et al.
British Journal of Cancer|September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David Hong, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic TrialAlison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular SubtypesJason C Chang, Michael Offin, Christina Falcon, et al.
Pageof 19